{"product_id":"vive-vrio-analysis","title":"Viveve Medical, Inc. (VIVE): VRIO Analysis [Mar-2026 Updated]","description":"\u003cbr\u003e\u003cp\u003eIs Viveve Medical, Inc. (VIVE) truly built for lasting success? This VRIO analysis cuts straight to the heart of their competitive advantage, scrutinizing if their key assets are Valuable, Rare, Inimitable, and Organized. Dive in now to see the distilled verdict on their sustainability and what it means for their future dominance.\u003c\/p\u003e\n\n\u003cbr\u003e\u003ch2\u003eViveve Medical, Inc. (VIVE) - VRIO Analysis: 1. Cryogen-cooled Monopolar Radiofrequency (CMRF) Technology\n\u003c\/h2\u003e\n\n\u003cp\u003eYou’re looking at the remnants of a once-promising technology, and that’s a tough spot to be in. The core issue here is that Viveve Medical, Inc. is no longer an operating entity as of November 2025; its key assets, including the CMRF technology, were acquired by InMode Ltd. in early 2024 following a Chapter 7 liquidation. So, when we assess VRIO, we are really assessing the technology's inherent strength now under a new, financially robust owner.\u003c\/p\u003e\n\n\u003cp\u003eThe CMRF technology itself was designed to offer non-invasive volumetric heating and neocollagenesis in a single session, which was a genuine differentiator in the women’s health device space. To give you a sense of the market it was aiming for, the broader energy-based aesthetic devices market is estimated to be valued at $20.62 Billion USD in 2025. Honestly, the technology had value, but the original company couldn't execute the commercialization plan effectively, leading to a last reported Trailing Twelve Months (TTM) revenue of only about $6.82 Million USD before the operational failure.\u003c\/p\u003e\n\n\u003cp\u003eHere’s the quick math on the inherent competitive position of the technology itself, separate from the original company’s management structure:\u003c\/p\u003e\n\n\u003ctable\u003e\n  \u003ctr\u003e\n    \u003ctd\u003eVRIO Dimension\u003c\/td\u003e\n    \u003ctd\u003eAssessment\u003c\/td\u003e\n    \u003ctd\u003eKey Data Point \/ Context\u003c\/td\u003e\n  \u003c\/tr\u003e\n  \u003ctr\u003e\n    \u003ctd\u003eValue\u003c\/td\u003e\n    \u003ctd\u003eYes\u003c\/td\u003e\n    \u003ctd\u003eUnique single-session treatment mechanism; fits into a $20.62 Billion market (2025 est.)\u003c\/td\u003e\n  \u003c\/tr\u003e\n  \u003ctr\u003e\n    \u003ctd\u003eRarity\u003c\/td\u003e\n    \u003ctd\u003eYes\u003c\/td\u003e\n    \u003ctd\u003eSpecific cryogen cooling + monopolar RF combination was unique in its niche.\u003c\/td\u003e\n  \u003c\/tr\u003e\n  \u003ctr\u003e\n    \u003ctd\u003eInimitability\u003c\/td\u003e\n    \u003ctd\u003eModerate\u003c\/td\u003e\n    \u003ctd\u003eCore physics is known, but the specific engineering and IP protection made it hard to copy quickly.\u003c\/td\u003e\n  \u003c\/tr\u003e\n  \u003ctr\u003e\n    \u003ctd\u003eOrganization\u003c\/td\u003e\n    \u003ctd\u003ePoor (Original) \/ Excellent (Acquirer)\u003c\/td\u003e\n    \u003ctd\u003eOriginal company failed to capture value; now owned by InMode Ltd.\u003c\/td\u003e\n  \u003c\/tr\u003e\n\u003c\/table\u003e\n\n\u003cp\u003eThe original company’s failure to organize around this asset is the whole story. They had something valuable and rare, but the path to sustained advantage was blocked by internal execution issues, specifically high cash burn and clinical trial costs. What this estimate hides is that the VRIO score for Viveve Medical, Inc. as an independent entity was ultimately a competitive failure, regardless of the technology’s potential.\u003c\/p\u003e\n\n\u003cp\u003eThe competitive advantage is no longer Viveve’s, which is the crucial takeaway for anyone analyzing the original stock. The advantage has been transferred, changing the dynamic entirely:\u003c\/p\u003e\n\u003cul\u003e\n  \u003cli\u003eCompetitive Advantage: Temporary, now held by InMode Ltd.\u003c\/li\u003e\n  \u003cli\u003eTechnology Survival: The IP is now integrated into a larger platform.\u003c\/li\u003e\n  \u003cli\u003eFinancial Reality: Viveve Medical, Inc.'s operational revenue for the 2025 fiscal year is $0 (zero).\u003c\/li\u003e\n  \u003cli\u003eMarket Position: InMode strengthens its women's wellness portfolio with the acquired patents.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003eIf you are tracking the technology's future, you need to follow InMode Ltd.’s integration strategy, not the shell of Viveve Medical, Inc. Finance: draft a memo outlining the IP transfer's impact on InMode's Q4 2025 guidance by next Tuesday.\u003c\/p\u003e\n\n\u003cbr\u003e\u003ch2\u003eViveve Medical, Inc. (VIVE) - VRIO Analysis: 2. Global Intellectual Property (IP) Portfolio\n\u003c\/h2\u003e\n\u003cp\u003e\u003cstrong\u003eValue:\u003c\/strong\u003e Patents covered the core system and specific applications like stress urinary incontinence (SUI), securing market exclusivity for years. The portfolio included U.S. Patent No. \u003cstrong\u003e11511110\u003c\/strong\u003e for SUI treatment utilizing dual-energy technology, issued in December \u003cstrong\u003e2022\u003c\/strong\u003e, and a prior U.S. SUI patent issued in the fall of \u003cstrong\u003e2020\u003c\/strong\u003e.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eRarity:\u003c\/strong\u003e Yes. A portfolio with international patents, including a U.S. patent for dual-energy tech, is rare for a company of its size. The international scope included patents issued in key markets.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eImitability:\u003c\/strong\u003e Difficult. Competitors face significant legal hurdles trying to replicate patented features.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eOrganization:\u003c\/strong\u003e The IP was a primary asset organized for defense and licensing, which ultimately led to its successful sale. The intellectual property assets were acquired on \u003cstrong\u003eJuly 25, 2023\u003c\/strong\u003e.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eCompetitive Advantage:\u003c\/strong\u003e Sustained. The patents provide a long-term barrier to entry, even under new ownership, as \u003cstrong\u003eall\u003c\/strong\u003e of Viveve's worldwide patents were transferred to the acquirer.\u003c\/p\u003e\n\u003cp\u003eThe scope of the intellectual property portfolio included specific jurisdictional grants:\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eThe portfolio was expanded by a patent issued in South Korea.\u003c\/li\u003e\n\u003cli\u003eA Canadian Patent issuance was announced in August \u003cstrong\u003e2021\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eTaiwan Patent No. \u003cstrong\u003e1720358\u003c\/strong\u003e was issued for the dual-energy technology device by the Taiwan Intellectual Property Office (TIPO).\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003eThe financial context surrounding the IP's value realization included a trailing twelve-month (TTM) revenue of \u003cstrong\u003e$6.82 Million USD\u003c\/strong\u003e before the operational wind-down, and a net loss of approximately \u003cstrong\u003e$18.7 million\u003c\/strong\u003e for the nine months ending September 30, \u003cstrong\u003e2023\u003c\/strong\u003e.\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003cth\u003eJurisdiction\u003c\/th\u003e\n\u003cth\u003ePatent Type\/Technology\u003c\/th\u003e\n\u003cth\u003ePatent Number\/Date Context\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eUnited States\u003c\/td\u003e\n\u003ctd\u003eSUI Treatment (Dual-Energy)\u003c\/td\u003e\n\u003ctd\u003eU.S. Patent No. \u003cstrong\u003e11511110\u003c\/strong\u003e (Issued Dec \u003cstrong\u003e2022\u003c\/strong\u003e)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eUnited States\u003c\/td\u003e\n\u003ctd\u003eSUI Treatment\u003c\/td\u003e\n\u003ctd\u003ePatent Issued Fall \u003cstrong\u003e2020\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eTaiwan\u003c\/td\u003e\n\u003ctd\u003eDual-Energy Technology\u003c\/td\u003e\n\u003ctd\u003ePatent No. \u003cstrong\u003e1720358\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCanada\u003c\/td\u003e\n\u003ctd\u003eGeneral IP Expansion\u003c\/td\u003e\n\u003ctd\u003ePatent Issuance Announced August \u003cstrong\u003e2021\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eSouth Korea\u003c\/td\u003e\n\u003ctd\u003eGeneral IP Expansion\u003c\/td\u003e\n\u003ctd\u003ePatent Issued Prior to April \u003cstrong\u003e2021\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\n\u003cbr\u003e\u003ch2\u003eViveve Medical, Inc. (VIVE) - VRIO Analysis: 3. International Regulatory Clearances\n\u003c\/h2\u003e\n\u003cp\u003e\u003cstrong\u003eValue:\u003c\/strong\u003e Approvals in \u003cstrong\u003emore than 50 countries\u003c\/strong\u003e allowed for immediate commercialization in key global markets outside the US.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eRarity:\u003c\/strong\u003e Fairly rare. Achieving this many clearances is a significant operational hurdle that many smaller firms never clear. As of October 2016, the system had received regulatory approval in \u003cstrong\u003e45 countries\u003c\/strong\u003e throughout the world.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eImitability:\u003c\/strong\u003e Difficult. Replicating the entire submission package and navigating foreign regulatory bodies takes substantial time and money. The company's global installed base was \u003cstrong\u003e857 Viveve Systems\u003c\/strong\u003e, with approximately \u003cstrong\u003e50,100 single-use treatment tips\u003c\/strong\u003e sold worldwide as of December 31, 2020.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eOrganization:\u003c\/strong\u003e The company had a dedicated regulatory team, but commercial execution was lacking. The Senior Vice President of Regulatory and Quality Affairs was listed as an executive.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eCompetitive Advantage:\u003c\/strong\u003e Temporary. The clearances, and specifically all of Viveve's worldwide patents, were transferred and registered under InMode Ltd. upon the acquisition of Intellectual Property Assets on \u003cstrong\u003eJuly 25, 2023\u003c\/strong\u003e.\u003c\/p\u003e\n\u003cp\u003eInternational Regulatory Milestones:\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003e\n\u003cstrong\u003eMore than 50 countries\u003c\/strong\u003e with regulatory approvals for vaginal laxity and\/or improvement in sexual function indications as of July 2021.\u003c\/li\u003e\n\u003cli\u003eRegulatory approval received in \u003cstrong\u003e47 countries\u003c\/strong\u003e as of October 13, 2016.\u003c\/li\u003e\n\u003cli\u003eRegulatory approval received in \u003cstrong\u003e27 countries\u003c\/strong\u003e as of August 10, 2016.\u003c\/li\u003e\n\u003cli\u003eAvailability in Japan via physician import license.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003eKey Operational Statistics (as of December 31, 2020):\u003c\/p\u003e\n\u003ctable\u003e\n\u003ctr\u003e\n\u003ctd\u003eMetric\u003c\/td\u003e\n\u003ctd\u003eAmount\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eGlobal Installed Base (Systems)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e857\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eSingle-Use Treatment Tips Sold (Worldwide)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e50,100\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/table\u003e\n\n\u003cbr\u003e\u003ch2\u003eViveve Medical, Inc. (VIVE) - VRIO Analysis: 4. US FDA Clearance for Electrocoagulation\/Hemostasis\n\u003c\/h2\u003e\n\u003cp\u003e\u003cstrong\u003eValue:\u003c\/strong\u003e Provided a baseline revenue stream from a US indication, even while pursuing the larger SUI indication.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eRarity:\u003c\/strong\u003e Moderate. Many devices get this general clearance, but it's a necessary step for US market access.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eImitability:\u003c\/strong\u003e Easy. This is a standard clearance pathway for many RF devices.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eOrganization:\u003c\/strong\u003e The company successfully navigated this, showing basic operational competence in US compliance.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eCompetitive Advantage:\u003c\/strong\u003e None. This is a table-stakes capability in the US medical device market.\u003c\/p\u003e\n\u003cp\u003eThe following table summarizes key regulatory milestones related to the US FDA clearance for electrocoagulation and hemostasis:\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003cth\u003eSystem Version\u003c\/th\u003e\n\u003cth\u003eFDA Clearance Type\u003c\/th\u003e\n\u003cth\u003eFDA 510(k) Number\u003c\/th\u003e\n\u003cth\u003eClearance Date\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eViveve System (Original)\u003c\/td\u003e\n\u003ctd\u003eGeneral Surgical Procedures for Electrocoagulation and Hemostasis\u003c\/td\u003e\n\u003ctd\u003eNot explicitly listed for initial clearance\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003eOctober 6, 2016\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eViveve 2.0 System\u003c\/td\u003e\n\u003ctd\u003eGeneral Surgical Procedures for Electrocoagulation and Hemostasis\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003eK190422\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003eJune 25, 2019\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eSubsequent Viveve System\u003c\/td\u003e\n\u003ctd\u003eSubstantial Equivalence to K180584 and K190422\u003c\/td\u003e\n\u003ctd\u003eK212678 (for Device Classification Name)\u003c\/td\u003e\n\u003ctd\u003eSubmission noted in \u003cstrong\u003eNovember 2020\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cp\u003eThe existence of this clearance facilitated international sales, as the company noted that products legally marketed in the U.S. could be exported without prior FDA notification.\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eInternational regulatory approvals\/clearances received for vaginal laxity and\/or improvement in sexual function indications in more than \u003cstrong\u003e50 countries\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eAs of \u003cstrong\u003eDecember 31, 2019\u003c\/strong\u003e, \u003cstrong\u003e\u003cstrong\u003e840\u003c\/strong\u003e Viveve Systems\u003c\/strong\u003e had been sold worldwide.\u003c\/li\u003e\n\u003cli\u003eAs of \u003cstrong\u003eDecember 31, 2019\u003c\/strong\u003e, approximately \u003cstrong\u003e\u003cstrong\u003e41,150\u003c\/strong\u003e single-use treatment tips\u003c\/strong\u003e had been sold worldwide.\u003c\/li\u003e\n\u003cli\u003eTotal revenue reported for the \u003cstrong\u003enine months ending September 30, 2023\u003c\/strong\u003e: \u003cstrong\u003e\u003cstrong\u003e$3.6 million\u003c\/strong\u003e\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eMarket capitalization as of \u003cstrong\u003eNovember 2025\u003c\/strong\u003e: approximately \u003cstrong\u003e\u003cstrong\u003e$4.29K\u003c\/strong\u003e\u003c\/strong\u003e (or \u003cstrong\u003e\u003cstrong\u003e$1.08 thousand\u003c\/strong\u003e\u003c\/strong\u003e).\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cbr\u003e\u003ch2\u003eViveve Medical, Inc. (VIVE) - VRIO Analysis: 5. Recurring Consumable Revenue Stream (Legacy Model)\n\u003c\/h2\u003e\n\u003cp\u003e\u003cstrong\u003eValue:\u003c\/strong\u003e The model was structured to generate high-margin, predictable revenue post-capital equipment sale. The consumable component, the single-use treatment tips, was the intended financial lifeblood. For the trailing twelve months (TTM) ending September 30, 2022, Consumable Sales accounted for an estimated 40% of total revenue, which was approximately $2.7 million of the $6.83 million TTM revenue. The overall Gross Profit Margin for the company was reported at only 20% of revenue in Q1 2022.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eRarity:\u003c\/strong\u003e While the razor-and-blade model is common, Viveve's inability to scale this stream to cover operating expenses before insolvency is a defining characteristic. The consumable revenue stream, while growing, was insufficient to sustain the business model, as evidenced by the sharp revenue decline to only $3.6 million in the nine months ending September 30, 2023.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eImitability:\u003c\/strong\u003e Moderate. The ability to generate recurring revenue was directly dependent on the installed base of the capital equipment. As of December 31, 2019, the installed base was 840 Viveve Systems worldwide, with approximately 41,150 single-use treatment tips sold.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eOrganization:\u003c\/strong\u003e The organization was structured to support the consumables stream through ongoing physician consultation and training following initial system installation. However, this structure was undermined by persistent negative cash flow, with a net loss of approximately $18.7 million reported for the nine months ending September 30, 2023.\u003c\/p\u003e\n\u003cp\u003eThe historical revenue breakdown illustrates the intended dependency on the recurring stream:\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003ctd\u003eRevenue Stream\u003c\/td\u003e\n\u003ctd\u003eEstimated % of Total (Pre-2024)\u003c\/td\u003e\n\u003ctd\u003eEstimated Amount (TTM Sep 30, 2022)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eCapital Equipment Sales (Viveve System)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e60%\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eApproximately \u003cstrong\u003e$4.1 million\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eConsumable Sales (Single-Use Treatment Tips)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e40%\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eApproximately \u003cstrong\u003e$2.7 million\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cp\u003eThe operational structure required consistent procedure volume to drive the consumable revenue, which was supported by the installed base:\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eInstalled Base (as of December 31, 2019): \u003cstrong\u003e840 Viveve Systems\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eCumulative Treatment Tips Sold (as of December 31, 2019): Approximately \u003cstrong\u003e41,150\u003c\/strong\u003e units.\u003c\/li\u003e\n\u003cli\u003eTotal Annual Revenue (FY 2021): \u003cstrong\u003e$6.43 million USD\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eRevenue for the nine months ending September 30, 2023: \u003cstrong\u003e$3.6 million\u003c\/strong\u003e.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003e\u003cstrong\u003eCompetitive Advantage:\u003c\/strong\u003e Temporary. The potential for a high-margin recurring revenue stream was never fully realized by Viveve as an independent entity. The core assets, including the technology driving this stream, were acquired by InMode Ltd. in early 2024.\u003c\/p\u003e\n\n\u003cbr\u003e\u003ch2\u003eViveve Medical, Inc. (VIVE) - VRIO Analysis: 6. Market Position in the VVA Therapy Segment\n\u003c\/h2\u003e\n\n\u003ch\u003eValue\u003c\/h\u003e\n\u003cp\u003eThe company was positioned to capture share in a market analysts projected to grow from USD 2.9 billion in 2025 to over USD 8.01 billion by 2035, registering a Compound Annual Growth Rate (CAGR) of 10.7% between 2026-2035.\u003c\/p\u003e\n\n\u003ch\u003eRarity\u003c\/h\u003e\n\u003cp\u003eModerate. The segment is growing, but Viveve was a smaller player against established firms. Key players in the broader vaginal and vulval inflammatory diseases treatment market include Hologic, Fotona, BTL Group of Companies, Alma Lasers, and Pfizer Inc.\u003c\/p\u003e\n\n\u003ch\u003eImitability\u003c\/h\u003e\n\u003cp\u003eEasy. Competitors can target the same patient population with different technologies.\u003c\/p\u003e\n\n\u003ch\u003eOrganization\u003c\/h\u003e\n\u003cp\u003eThe market awareness was built through clinical data, but the sales force couldn't scale effectively. Viveve Medical's Trailing Twelve Months (TTM) Revenue as of 2022 was $6.82 Million USD, with an employee count of 47.\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eViveve Medical reported total assets of 12.15 million in the latest quarter.\u003c\/li\u003e\n\u003cli\u003eNet Assets as of September 2022 were $1.18 Million USD.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003ch\u003eCompetitive Advantage\u003c\/h\u003e\n\u003cp\u003eNone. The market opportunity is open to all, and Viveve's share is now zero.\u003c\/p\u003e\n\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue\u003c\/th\u003e\n\u003cth\u003eContext\/Year\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eVVA Therapy Market Size (Projected)\u003c\/td\u003e\n\u003ctd\u003eUSD 2.9 billion\u003c\/td\u003e\n\u003ctd\u003e2025\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eVVA Therapy Market Size (Projected)\u003c\/td\u003e\n\u003ctd\u003eUSD 8.01 billion\u003c\/td\u003e\n\u003ctd\u003e2035\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eVVA Therapy Market CAGR\u003c\/td\u003e\n\u003ctd\u003e10.7%\u003c\/td\u003e\n\u003ctd\u003e2026-2035\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eViveve TTM Revenue\u003c\/td\u003e\n\u003ctd\u003e$6.82 Million USD\u003c\/td\u003e\n\u003ctd\u003e2022\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eViveve Employee Count\u003c\/td\u003e\n\u003ctd\u003e47\u003c\/td\u003e\n\u003ctd\u003eLatest reported\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\n\u003cbr\u003e\u003ch2\u003eViveve Medical, Inc. (VIVE) - VRIO Analysis: 7. Global Sales and Distribution Network (Legacy)\n\u003c\/h2\u003e\n\u003cp\u003e\u003cstrong\u003eValue:\u003c\/strong\u003e Established relationships with direct sales teams and international distributors across key regions like Asia Pacific and Europe.\u003c\/p\u003e\n\u003cp\u003eThe network supported a global footprint, with historical revenue showing a geographic split in a prior fiscal year:\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003cth\u003eRegion\u003c\/th\u003e\n\u003cth\u003eHistorical Revenue Amount (USD)\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eUnited States\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$3.7 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAsia Pacific\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$2.65 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cp\u003e\u003cstrong\u003eRarity:\u003c\/strong\u003e Moderate. Building a global footprint takes years and significant upfront investment.\u003c\/p\u003e\n\u003cp\u003eThe total Trailing Twelve Months (TTM) revenue before operational wind-down was reported as \u003cstrong\u003e$6.82 Million USD\u003c\/strong\u003e.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eImitability:\u003c\/strong\u003e Difficult. Relationships are personal and take time for competitors to replicate.\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eThe distribution network was established to support \u003cstrong\u003e895\u003c\/strong\u003e installed systems worldwide.\u003c\/li\u003e\n\u003cli\u003eThe revenue model relied on recurring consumable sales, which historically accounted for an estimated \u003cstrong\u003e40%\u003c\/strong\u003e (approximately \u003cstrong\u003e$2.7 million\u003c\/strong\u003e of the estimated \u003cstrong\u003e$6.8 million\u003c\/strong\u003e TTM revenue).\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003e\u003cstrong\u003eOrganization:\u003c\/strong\u003e This network was a major cost center that ultimately strained the balance sheet.\u003c\/p\u003e\n\u003cp\u003eSelling, General \u0026amp; Admin expenses for the TTM ending September 2022 were \u003cstrong\u003e$13.82 million\u003c\/strong\u003e (in millions USD).\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eCompetitive Advantage:\u003c\/strong\u003e Temporary. The network was likely absorbed or dismantled during the asset acquisition.\u003c\/p\u003e\n\u003cp\u003eAll worldwide patents and intellectual property assets were acquired by InMode Ltd. on \u003cstrong\u003eJuly 25, 2023\u003c\/strong\u003e.\u003c\/p\u003e\n\n\u003cbr\u003e\u003ch2\u003eViveve Medical, Inc. (VIVE) - VRIO Analysis: 8. Clinical Data Set on Vaginal Laxity\n\u003c\/h2\u003e\n\u003cp\u003e\u003cstrong\u003eValue:\u003c\/strong\u003e A body of evidence supporting the safety and efficacy of the CMRF treatment for its primary indication, despite the primary endpoint not being met in the pivotal U.S. trial.\u003c\/p\u003e\n\u003cp\u003eThe VIVEVE II trial, evaluating CMRF technology for improvement of sexual function in women following vaginal childbirth, included \u003cstrong\u003e220 subjects\u003c\/strong\u003e completing 12-month follow-up. The study reported \u003cstrong\u003eno serious device-related adverse events\u003c\/strong\u003e.\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eActive Treatment (CMRF)\u003c\/th\u003e\n\u003cth\u003eSham Treatment\u003c\/th\u003e\n\u003cth\u003eDifference\u003c\/th\u003e\n\u003cth\u003eStatistical Significance (p-value)\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eAdjusted Mean Change in Total FSFI Score at 12 Months\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e9.8\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e9.0\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e0.8\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e0.3942\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRF Energy Delivered\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e90 Joules\/cm²\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e1 Joule\/cm²\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eN\/A\u003c\/td\u003e\n\u003ctd\u003eN\/A\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cp\u003eThe clinical data set also included the U.S. Pivotal PURSUIT trial for stress urinary incontinence (SUI), which released topline results in \u003cstrong\u003eJanuary 2023\u003c\/strong\u003e, also failing to meet its primary endpoint of a statistically significant increase in patients experiencing over a \u003cstrong\u003e50% reduction in urine leakage\u003c\/strong\u003e versus sham at \u003cstrong\u003e12 months\u003c\/strong\u003e.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eRarity:\u003c\/strong\u003e Moderate. Generating high-quality, peer-reviewed clinical data is expensive and not guaranteed. Viveve Medical's Research \u0026amp; Development expenses peaked at \u003cstrong\u003e$13.26 million\u003c\/strong\u003e in \u003cstrong\u003eFY 2018\u003c\/strong\u003e.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eImitability:\u003c\/strong\u003e Difficult. Competitors must fund their own trials to generate comparable data. The company's global installed base was \u003cstrong\u003e865 Viveve® Systems\u003c\/strong\u003e as of \u003cstrong\u003eSeptember 30, 2020\u003c\/strong\u003e.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eOrganization:\u003c\/strong\u003e The data was central to marketing and regulatory submissions, showing a clear focus. The company reported total revenue of \u003cstrong\u003e$1.5 million\u003c\/strong\u003e for the third quarter of \u003cstrong\u003e2020\u003c\/strong\u003e.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eCompetitive Advantage:\u003c\/strong\u003e Temporary. The data package was part of the IP sale to InMode, which acquired \u003cstrong\u003eall\u003c\/strong\u003e of Viveve's worldwide patents on \u003cstrong\u003eJuly 25, 2023\u003c\/strong\u003e. Viveve's Trailing Twelve Months (TTM) revenue before the operational wind-down was reported as \u003cstrong\u003e$6.83 Million USD\u003c\/strong\u003e.\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eThe clinical data set supported the use of the CMRF technology, which utilizes gentle cooling to generate neocollagenesis in a single in-office session.\u003c\/li\u003e\n\u003cli\u003eThe company's FY 2021 revenue was \u003cstrong\u003e$6.43 million\u003c\/strong\u003e.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cbr\u003e\u003ch2\u003eViveve Medical, Inc. (VIVE) - VRIO Analysis: 9. Brand Recognition in Intimate Health (Legacy)\n\u003c\/h2\u003e\n\u003cp\u003e\n\u003ch\u003e\u003ch\u003eValue: The name was known among specialists focused on non-invasive women's health solutions, offering a degree of trust.\u003c\/h\u003e\u003c\/h\u003e\n\u003c\/p\u003e\n\u003cp\u003e\nThe brand was associated with the Viveve System, which utilized a proprietary method of delivering monopolar radiofrequency (RF) energy with cryogen surface cooling for treating tissue. The last reported trailing twelve-month (TTM) revenue before the operational wind-down was approximately $6.83 Million USD. Total Current Assets as of Sep 30, 2022, amounted to 9.6m USD.\n\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003ctd\u003eMetric\u003c\/td\u003e\n\u003ctd\u003eValue\u003c\/td\u003e\n\u003ctd\u003eDate\/Period\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eLast Reported TTM Revenue\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$6.83 Million USD\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003ePre-Bankruptcy\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eTotal Current Assets\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e9.6m USD\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eSep 30, 2022\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eDebt-to-Equity Ratio\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e5.08\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003ePre-Bankruptcy\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eR\u0026amp;D Spend Peak\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$13.26 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e2018\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e2021 Revenue\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$6.43 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e2021\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eIP Asset Acquisition Date\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003eJuly 25, 2023\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eTransaction\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePost-Bankruptcy Market Cap\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$4.29 thousand\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eNovember 2025\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cp\u003e\n\u003ch\u003e\u003ch\u003eRarity: Low. Brand recognition is built over time, but it is easily overshadowed by new market entrants.\u003c\/h\u003e\u003c\/h\u003e\n\u003c\/p\u003e\n\u003cp\u003e\nThe company's pursuit of the SUI indication involved significant investment, with R\u0026amp;D spend peaking at $13.26 million in 2018 against a 2021 revenue of only $6.43 million.\n\u003c\/p\u003e\n\u003cp\u003e\n\u003ch\u003e\u003ch\u003eImitability: Difficult. Brand equity is hard to build, but it erodes quickly without active marketing spend.\u003c\/h\u003e\u003c\/h\u003e\n\u003c\/p\u003e\n\u003cp\u003e\nThe core technology involved a proprietary, controlled cryogen surface cooling enabling deep volumetric heating of vaginal tissue. The stock price fell by approximately 75.00% over the last 12 months leading up to November 2025 data.\n\u003c\/p\u003e\n\u003cp\u003e\n\u003ch\u003e\u003ch\u003eOrganization: The brand was supported by a commitment to education, but the company’s financial distress damaged perception.\u003c\/h\u003e\u003c\/h\u003e\n\u003c\/p\u003e\n\u003cp\u003e\nThe company filed for Chapter 11 bankruptcy in late 2023, followed by a conversion to Chapter 7 liquidation. The core assets were acquired by InMode Ltd. on July 25, 2023.\n\u003c\/p\u003e\n\u003cp\u003e\n\u003ch\u003e\u003ch\u003eCompetitive Advantage: None. The brand equity is now associated with the acquirer or is fading fast.\u003c\/h\u003e\u003c\/h\u003e\n\u003c\/p\u003e\n\u003cp\u003e\nThe market capitalization as of November 2025 reflected a distressed entity, sitting at approximately $4.29 thousand.\n\u003c\/p\u003e\n\u003cp\u003e\n\u003cstrong\u003eFinance: draft a memo detailing the final asset valuation used in the 2024 InMode transaction by next Tuesday.\u003c\/strong\u003e\n\u003c\/p\u003e","brand":"dcf.fm","offers":[{"title":"Default Title","offer_id":45516278595733,"sku":"vive-vrio-analysis","price":7.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0630\/5189\/0837\/files\/vive-vrio-analysis.png?v=1740229964","url":"https:\/\/dcf-model.com\/products\/vive-vrio-analysis","provider":"AI-Powered Discounted Cash Flow Model Templates","version":"1.0","type":"link"}